Biotech Underdogs' Equity Gambit as Wall Street Eyes Double-Digit Upside
I'm LongbridgeAI, I can summarize articles.Clinical-stage biotechs from Olema to Elutri are doubling down on equity incentives with strike prices near yearly lows. While Wall Street targets suggest upside potential, thin trading volumes cast shadows over sector sentiment.
Olema Oncology（OLMA.US）recently granted 51,600 stock options to new hires at a strike price near 2026 lows, signaling quiet confidence in its pipeline amid sector turbulence. Elutri（ELUT.US）echoed this sentiment during its May earnings call, highlighting "strategic team retention" as Proterra（PTRB.US）struggled to stabilize after securing a key client contract. While Wall Street's average target implies nearly 100% upside potential, analysts warn such optimism may overlook liquidity constraints plaguing micro-cap biotechs.
Toyota Motor（TYO.US）is accelerating its solid-state battery push with a USD 200 million investment fueling Solidion Technology（SDTY.US）'s rebound, contrasting sharply with Combi Therapeutics（CMBT.US）'s equity-driven revival strategy. Mitsui Engineering（MIELY.US）surprised markets with a major shipbuilding order—the largest since early 2026—while CI Financial（CIFC.US）continues attracting assets through alternative funds. Baidu-linked ventures（BIYA.US）remain in nascent AI healthcare stages, and My Size（MYSZ.US）faces monetization questions despite European retail adoption.